August 2026– date –
-
PROTACs vs. Molecular Glues: Comparing Targeted Protein Degraders for Size and Permeability in Drug Selection
Drug Target Review UK Overview PROTACs and molecular glues represent two distinct strategies for targeted protein degradation, each with unique advantages and challenges. PROTACs are bifunctional molecules that recruit an E3 ligase to a ... -
siRNA Therapy Successfully Switches Off Harmful Genes: FDA-Approved Patisiran and Other Drugs for Hereditary Amyloidosis
Works in Progress Magazine UK Overview siRNA therapy is emerging as a promising treatment to slow or halt disease progression by temporarily silencing specific genes. For conditions like hereditary transthyretin amyloidosis, FDA-approved... -
New Blood-Brain Barrier Penetration Strategies: Peptides and ‘Trojan Horse’ Approaches Revolutionize Brain Drug Delivery
Facebook USA Overview The blood-brain barrier (BBB) blocks approximately 95% of drugs, severely impeding treatment for brain disorders. Researchers are developing novel techniques to bypass this barrier, including 'Trojan horse' approach... -
Northeastern Graduate Research Highlights Limits of AI in Drug Discovery: Human Expertise Remains Crucial for Complex Research
Northeastern University USA Overview Northeastern University graduate students examined claims that AI would completely transform drug discovery, concluding that while useful for simple tasks, AI still generates inaccurate results in com... -
Antibody-Drug Conjugate (ADC) Development Guide: Precise Design of Monoclonal Antibodies, Linkers, and Payloads is Key
Allucent USA Overview Antibody-Drug Conjugates (ADCs) combine three engineered components—a tumor-targeting monoclonal antibody, a chemical linker, and an active payload—to deliver potent cancer therapy. Upon binding to the target, ADCs ... -
Johns Hopkins’ N4-Acetylcytidine (ac4C) mRNA Platform Boosts Therapeutic Protein Production Beyond Industry Standard
Johns Hopkins Medicine USA Overview Scientists at Johns Hopkins Medicine have reported an experimental N4-acetylcytidine (ac4C) mRNA platform capable of delivering next-generation mRNA therapeutics for infectious diseases, cancer, and au... -
Bispecific Antibodies Revolutionize Cancer Therapy: 15 FDA-Approved, Over 600 in Clinical Trials as T-Cell Engagers
BroadPharm USA Overview Bispecific antibodies (BsAbs) are engineered to simultaneously bind two different antigens or epitopes, offering superior disease target recognition and biological effect modulation compared to conventional monocl... -
AI Transforms Drug Discovery: Machine Learning Drastically Cuts Costs & Timelines, Yields 75 Clinical Candidates
Facebook USA Overview AI is accelerating drug discovery and significantly reducing costs by leveraging machine learning to design candidate molecules and drastically narrow the vast protein structure search space. Algorithms like generat... -
AI Accelerates Drug Discovery: AlphaFold, Generative Models Drive R&D Efficiency & Clinical Pipeline Growth
Markets Insider USA Overview AI has dramatically accelerated drug discovery over the past five years through advancements in protein structure prediction, generative chemistry, and phenotypic screening. Tools like DeepMind's AlphaFold ha... -
Honda Inaugurates Solid-State Battery Cell Production Demo Line in Sakura R&D Facility, Targeting 2026 Launch
How-To Geek Japan Overview Honda has launched a demonstration production line for solid-state battery cells at its Sakura R&D facility, aiming for mass production to commence in 2026. This strategic move marks a critical step towards...
